...
机译:DAA故障几乎所有HCV基因型中频繁的NS5A和多款抗性:二线方案的机会是什么?
Univ Roma Tor Vergata Dept Expt Med &
Surg Via Montpellier 1 I-00133 Rome Italy;
Univ Roma Tor Vergata Dept Expt Med &
Surg Via Montpellier 1 I-00133 Rome Italy;
Univ Roma Tor Vergata Dept Expt Med &
Surg Via Montpellier 1 I-00133 Rome Italy;
Policlin Fdn San Matteo Mol Virol Pavia Italy;
Univ Hosp Messina Dept Internal Med Messina Italy;
Univ Campania Luigi Vanvitelli Infect Dis &
Viral Hepatitis Unit Naples Italy;
IRCCS AOU San Martino IST Hyg Unit Genoa Italy;
Amedeo Savoia Hosp ASL Citta Torino Lab Microbiol &
Virol Turin Italy;
Siena Univ Hosp Virol Siena Italy;
Univ Hosp Pisa Hepatol Unit Pisa Italy;
Univ Roma Tor Vergata Dept Expt Med &
Surg Via Montpellier 1 I-00133 Rome Italy;
Univ Roma Tor Vergata Dept Expt Med &
Surg Via Montpellier 1 I-00133 Rome Italy;
St Orsola Malpighi Hosp Bologna Microbiol &
Virol Unit Bologna Italy;
Univ Hosp Microbiol Lab Modena Italy;
Policlin Fdn San Matteo Mol Virol Pavia Italy;
Univ Hosp Messina Dept Internal Med Messina Italy;
Univ Roma Tor Vergata Dept Expt Med &
Surg Via Montpellier 1 I-00133 Rome Italy;
Univ Roma Tor Vergata Dept Expt Med &
Surg Via Montpellier 1 I-00133 Rome Italy;
机译:DAA故障几乎所有HCV基因型中频繁的NS5A和多款抗性:二线方案的机会是什么?
机译:Ledipasvir加上Sofosbuvir作为HCV基因型的救生疗法,以先前NS5A抑制剂方案的故障
机译:DAA治疗失败与GT 3 HCV肝硬化和NS5A抗性序列(RAS)的选择 - 对救助治疗的影响
机译:在接受DAA方案治疗的HCV基因型3感染者中肝细胞癌经常发生并在治疗后早期发生
机译:在里约热内卢/巴西的DAAs治疗慢性HCV感染:NS5A和NS5B基因中的SVR速率和基线抗性分析